Compass Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0.0 | $0.8 | $0.0 | — | — |
| Operating income | -$72.8 | -$56.6 | -$50.4 | -$41.7 | -$81.9 |
| Net income | -$66.5 | -$49.4 | -$42.5 | -$39.2 | -$82.2 |
| Cash Flow Statement | |||||
| Free cash flow | -$49.2 | -$44.9 | -$40.6 | -$34.3 | -$21.2 |
Shares outstanding 180.1M
Annual filing data through FY ended December 31, 2025; float as of September 12, 2026.